P
PharmaCyte Biotech, Inc.
PMCBCIK 0001157075NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)NevadaFY ends Apr 30
Period
FY 2025
Revenue
$0
Net Income
$30.66M
Total Assets
$55.17M
Equity
$51.89M
Shares Out
10.74M
Op. Cash Flow
$-2.98M
Business
PharmaCyte Biotech is a development-stage biotechnology company focused on cellular therapies for cancer using its proprietary Cell-in-a-Box® cellulose-based live cell encapsulation technology. The company is developing CypCaps™, its current-generation product candidate, primarily for treatment of locally advanced, inoperable, non-metastatic pancreatic cancer. PharmaCyte operates through an exclusive license agreement with SG Austria Pte. Ltd., which owns and manufactures the encapsulation technology, and holds Orphan Drug designation in the U.S. and European Union for its pancreatic cancer therapy.
Summary from 10-K filed 2025-08-11
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and development costs | 438,416 | 407,431 | 468,536 | 690,937 | 916,249 | |
| Intangible asset impairment | 0 | 2 | 0 | — | — | |
| General and administrative | 4 | 6 | 1 | 1 | 418,145 | |
| Total operating expenses | 4 | 9 | 6 | 4 | 4 | |
| Loss from operations | −4 | −9 | −6 | −4 | −4 | |
| Interest income | 1 | 3 | 2 | 157,645 | 0 | |
| Change in fair value of warrant liability | 10 | 3 | 0 | — | — | |
| Change in fair value of derivative liability | 2 | 586,000 | 0 | — | — | |
| Change in fair value of convertible note receivable Femasys | 941,000 | 1 | 0 | — | — | |
| Change in fair value of warrant asset Femasys | −2 | 2 | — | — | — | |
| Change in fair value of investment TNF | 5 | 0 | — | — | — | |
| Change in fair value of warrant assets - TNF | −2 | 0 | — | — | — | |
| Gain on investment in preferred stock TNF | 21 | 0 | — | — | — | |
| Unrealized gain on marketable securities | 66,316 | 0 | — | — | — | |
| Loss on legal settlement | −2 | 0 | — | — | — | |
| Loss on long term asset | 0 | −2 | 0 | — | — | |
| Other income (expense), net | −965 | 191,145 | 202,002 | −4,283 | 71,745 | |
| Total other income (expense), net | 35 | 9 | 2 | 152,853 | 71,745 | |
| Income tax benefit (expense) | 0 | 0 | — | — | — | |
| Net income | 31 | 333,763 | −4 | −4 | −4 | |
| Preferred stock dividends | −1 | −3 | 0 | — | — | |
| Undistributed income to Series B convertible preferred stock | −3 | — | — | — | — | |
| Preferred stock accretion | −3 | −15 | 0 | — | — | |
| Net income (loss) attributable to common stockholders | 23 | −17 | −4 | — | — | |
| Basic income (loss) per share attributable to common stockholders | 3.19 | −1.8 | −0.22 | −0.27 | −2.45 | |
| Diluted income (loss) per share attributable to common stockholders | 3.19 | −1.8 | −0.22 | −0.27 | −2.45 | |
| Weighted average shares outstanding basic | 7 | 10 | 19 | 16 | 1 | |
| Weighted average shares outstanding diluted | 7 | 10 | 19 | 16 | 1 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 15 | 50 | 68 | 85 | — | |
| Marketable equity securities | 366,316 | 0 | — | — | — | |
| Warrant asset TNF - current | 3 | 0 | — | — | — | |
| Convertible Note receivable Femasys - current | 4 | 0 | — | — | — | |
| Prepaid expenses and other current assets | 223,759 | 259,800 | 107,681 | 94,172 | 73,131 | |
| Total current assets | 22 | 50 | 68 | 85 | 2 | |
| Intangible assets | 2 | 2 | 4 | 4 | — | |
| Investment in preferred stock TNF | 22 | 0 | — | — | — | |
| Warrant assets TNF - non current | 6 | 0 | — | — | — | |
| Convertible note receivable Femasys - non current | 0 | 3 | — | — | — | |
| Warrant assets - Femasys | 3 | 5 | — | — | — | |
| Other assets | 7,688 | 7,688 | 7,688 | 7,688 | 7,372 | |
| Total other assets | 33 | 9 | 5 | 5 | 5 | |
| Total Assets | 55 | 60 | 73 | 91 | 7 | |
| Accounts payable | 399,204 | 389,369 | 128,281 | 205,361 | 172,261 | |
| Accrued expenses | 3 | 735,199 | 458,300 | 499,009 | 552,517 | |
| Accrued Series B convertible preferred stock redemption and dividends payable | 0 | 6 | 0 | — | — | |
| Total current liabilities | 3 | 7 | 586,581 | 704,370 | 724,778 | |
| Long-term portion of accrued expenses | 25,000 | 0 | — | — | — | |
| Warrant liability | 338,000 | 11 | 0 | — | — | |
| Derivative liability | 0 | 2 | 0 | — | — | |
| Total other liabilities | 363,000 | 13 | 0 | — | — | |
| Total Liabilities | 3 | 20 | 586,581 | 704,370 | 724,778 | |
| Commitments and Contingencies (Note 9) | — | — | — | — | — | |
| Preferred stock value | 0 | 0 | 0 | — | — | |
| Common stock, authorized: 200,000,000 shares, $0.0001 par value; shares issued 21,672,095, shares outstanding 6,795,779 as of April 30, 2025, and shares issued 21,672,078, shares outstanding 8,037,624 as of April 30, 2024 | 2,167 | 2,167 | 2,160 | 2,072 | 159 | |
| Additional paid-in capital | 181 | 185 | 202 | 202 | 114 | |
| Accumulated deficit | −85 | −116 | −116 | −112 | −107 | |
| Treasury stock, at cost, 14,876,316 and 13,634,454 shares as of April 30, 2025, and 2024, respectively | −45 | −42 | −14 | 0 | — | |
| Accumulated other comprehensive loss | −23,869 | −23,511 | −23,003 | −15,757 | −20,382 | |
| Total stockholders' equity | 52 | 28 | 73 | 90 | 7 | |
| Total Liabilities, Convertible Preferred Stock and Stockholders' Equity | 55 | 60 | 73 | 91 | 7 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-04-30 | FY 2024 2024-04-30 | FY 2023 2023-04-30 | FY 2022 2022-04-30 | FY 2021 2021-04-30 |
|---|---|---|---|---|---|---|
| Non-cash interest income | −300,000 | 0 | — | — | — | |
| Non-cash warrant liability | 469,000 | 0 | — | — | — | |
| Other non-cash income | 0 | −195,000 | 171,744 | — | — | |
| Stock-based compensation | 478,637 | 674,693 | 7,334 | 33,146 | 194,261 | |
| Change in fair value of convertible note receivable - Femasys | −941,000 | −1 | — | — | — | |
| (Increase) decrease in prepaid expenses and other current assets | 36,041 | −152,119 | −13,509 | −21,041 | 69,653 | |
| Increase in accounts payable | 9,835 | 261,090 | −242,948 | — | — | |
| Increase in accrued expenses | 1 | 189,923 | −40,709 | — | — | |
| Net cash used in operating activities | −3 | −2 | −4 | −4 | −3 | |
| Investment in preferred stock and warrants | −7 | 0 | — | — | — | |
| Investment convertible note receivable and warrants | 0 | −5 | — | — | — | |
| Net cash used in investing activities | −7 | −5 | 0 | 0 | 0 | |
| Repurchase of common stock, net | −3 | −28 | −14 | 0 | — | |
| Proceeds from issuance of preferred stock, net of transaction costs | 0 | 34 | 0 | — | 0 | |
| Redemption of preferred stock | −22 | −16 | 0 | — | — | |
| Proceeds from warrant exercise | 0 | 70 | 880 | 0 | — | |
| Net cash used in financing activities | −25 | −11 | −14 | 87 | 5 | |
| Effect of currency rate exchange on cash and cash equivalents | −358 | −508 | −7,246 | 4,625 | — | |
| Net decrease in cash and cash equivalents | −35 | −18 | −17 | 83 | 1 | |
| Cash paid during the year for income taxes | 0 | 1,600 | 0 | 1,600 | 800 | |
| Non-cash derivative liability at initial fair value | 0 | 3 | 0 | — | — | |
| Non-cash warrant liability at initial fair value | 0 | 14 | 0 | — | — | |
| Accrued Series B Convertible Preferred Stock dividends | — | 22 | — | — | — | |
| Series B Convertible Preferred stock dividends | 1 | 0 | — | — | — | |
| Excise tax accrued on repurchase of common stock | 25,424 | 281,976 | 0 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is PharmaCyte Biotech, Inc.'s CIK number?
PharmaCyte Biotech, Inc.'s SEC CIK number is 0001157075 (1157075). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find PharmaCyte Biotech, Inc.'s SEC filings?
All of PharmaCyte Biotech, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.